Specific treatments with regard to the presence of specific musculoskeletal manifestations and the personal history of psoriasis in patients with peripheral spondyloarthritis
| . | Peripheral arthritis (n = 410) . | Enthesitis (n = 248) . | Dactylitis (n = 100) . | Root jointadisease (n = 192) . | Axial disease (n = 238) . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | Patients without personal history of psoriasis (n = 335) . | Patients with personal history of psoriasis (n = 75) . | P . | Patients without personal history of psoriasis (n = 194) . | Patients with personal history of psoriasis (n = 54) . | P . | Patients without personal history of psoriasis (n = 70) . | Patients with personal history of psoriasis (n = 30) . | P . | Patients without personal history of psoriasis (n = 162) . | Patients with personal history of psoriasis (n = 30) . | P . | Patients without personal history of psoriasis (n = 19)3 . | Patients with personal history of psoriasis (n = 45) . | P . |
| Any treatment, n (%) | 314 (93.7) | 71 (94.7) | >0.999 | 126 (64.9) | 32 (59.3) | 0.522 | 49 (70.0) | 17 (56.7) | 0.250 | 141 (87.0) | 24 (80.0) | 0.388 | 166 (86.0) | 37 (82.2) | 0.491 |
| NSAIDs, n (%) | 325 (97.0) | 73 (97.3) | >0.999 | 121 (96.0) | 31 (96.9) | >0.999 | 45 (91.8) | 15 (88.2) | 0.643 | 137 (97.2) | 21 (87.5) | 0.064 | 165 (99.4) | 37 (100.0) | >0.999 |
| Systemic GCs, n (%) | 175 (52.2) | 30 (40.0) | 0.073 | 51 (40.5) | 9 (28.1) | 0.226 | NC | NC | NC | NC | NC | NC | NC | NC | NC |
| Local injections of GCs, n (%) | 137 (40.9) | 22 (29.3) | 0.067 | 18 (14.3) | 6 (18.8) | 0.582 | 11 (22.4) | 4 (23.5) | >0.999 | 27 (19.1) | 5 (20.8) | 0.786 | NC | NC | NC |
| csDMARDs, n (%) | 286 (85.4) | 62 (82.7) | 0.593 | 83 (65.9) | 18 (56.3) | 0.312 | 30 (61.2) | 9 (52.9) | 0.578 | 106 (75.2) | 16 (66.7) | 0.451 | 103 (62.0) | 26 (70.3) | 0.450 |
| bDMARDs, n (%) | 124 (37.0) | 43 (57.3) | 0.002 | 37 (29.4) | 19(59.4) | 0.003 | 11 (22.4) | 9 (52.9) | 0.031 | 39 (27.7) | 14 (58.3) | 0.004 | 63 (38.0) | 22 (59.5) | 0.026 |
| . | Peripheral arthritis (n = 410) . | Enthesitis (n = 248) . | Dactylitis (n = 100) . | Root jointadisease (n = 192) . | Axial disease (n = 238) . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | Patients without personal history of psoriasis (n = 335) . | Patients with personal history of psoriasis (n = 75) . | P . | Patients without personal history of psoriasis (n = 194) . | Patients with personal history of psoriasis (n = 54) . | P . | Patients without personal history of psoriasis (n = 70) . | Patients with personal history of psoriasis (n = 30) . | P . | Patients without personal history of psoriasis (n = 162) . | Patients with personal history of psoriasis (n = 30) . | P . | Patients without personal history of psoriasis (n = 19)3 . | Patients with personal history of psoriasis (n = 45) . | P . |
| Any treatment, n (%) | 314 (93.7) | 71 (94.7) | >0.999 | 126 (64.9) | 32 (59.3) | 0.522 | 49 (70.0) | 17 (56.7) | 0.250 | 141 (87.0) | 24 (80.0) | 0.388 | 166 (86.0) | 37 (82.2) | 0.491 |
| NSAIDs, n (%) | 325 (97.0) | 73 (97.3) | >0.999 | 121 (96.0) | 31 (96.9) | >0.999 | 45 (91.8) | 15 (88.2) | 0.643 | 137 (97.2) | 21 (87.5) | 0.064 | 165 (99.4) | 37 (100.0) | >0.999 |
| Systemic GCs, n (%) | 175 (52.2) | 30 (40.0) | 0.073 | 51 (40.5) | 9 (28.1) | 0.226 | NC | NC | NC | NC | NC | NC | NC | NC | NC |
| Local injections of GCs, n (%) | 137 (40.9) | 22 (29.3) | 0.067 | 18 (14.3) | 6 (18.8) | 0.582 | 11 (22.4) | 4 (23.5) | >0.999 | 27 (19.1) | 5 (20.8) | 0.786 | NC | NC | NC |
| csDMARDs, n (%) | 286 (85.4) | 62 (82.7) | 0.593 | 83 (65.9) | 18 (56.3) | 0.312 | 30 (61.2) | 9 (52.9) | 0.578 | 106 (75.2) | 16 (66.7) | 0.451 | 103 (62.0) | 26 (70.3) | 0.450 |
| bDMARDs, n (%) | 124 (37.0) | 43 (57.3) | 0.002 | 37 (29.4) | 19(59.4) | 0.003 | 11 (22.4) | 9 (52.9) | 0.031 | 39 (27.7) | 14 (58.3) | 0.004 | 63 (38.0) | 22 (59.5) | 0.026 |
Shoulder and hip joints. bDMARD: biologic DMARD; csDMARD: conventional synthetic DMARD; GC: glucocorticoid; NC: not collected.
Specific treatments with regard to the presence of specific musculoskeletal manifestations and the personal history of psoriasis in patients with peripheral spondyloarthritis
| . | Peripheral arthritis (n = 410) . | Enthesitis (n = 248) . | Dactylitis (n = 100) . | Root jointadisease (n = 192) . | Axial disease (n = 238) . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | Patients without personal history of psoriasis (n = 335) . | Patients with personal history of psoriasis (n = 75) . | P . | Patients without personal history of psoriasis (n = 194) . | Patients with personal history of psoriasis (n = 54) . | P . | Patients without personal history of psoriasis (n = 70) . | Patients with personal history of psoriasis (n = 30) . | P . | Patients without personal history of psoriasis (n = 162) . | Patients with personal history of psoriasis (n = 30) . | P . | Patients without personal history of psoriasis (n = 19)3 . | Patients with personal history of psoriasis (n = 45) . | P . |
| Any treatment, n (%) | 314 (93.7) | 71 (94.7) | >0.999 | 126 (64.9) | 32 (59.3) | 0.522 | 49 (70.0) | 17 (56.7) | 0.250 | 141 (87.0) | 24 (80.0) | 0.388 | 166 (86.0) | 37 (82.2) | 0.491 |
| NSAIDs, n (%) | 325 (97.0) | 73 (97.3) | >0.999 | 121 (96.0) | 31 (96.9) | >0.999 | 45 (91.8) | 15 (88.2) | 0.643 | 137 (97.2) | 21 (87.5) | 0.064 | 165 (99.4) | 37 (100.0) | >0.999 |
| Systemic GCs, n (%) | 175 (52.2) | 30 (40.0) | 0.073 | 51 (40.5) | 9 (28.1) | 0.226 | NC | NC | NC | NC | NC | NC | NC | NC | NC |
| Local injections of GCs, n (%) | 137 (40.9) | 22 (29.3) | 0.067 | 18 (14.3) | 6 (18.8) | 0.582 | 11 (22.4) | 4 (23.5) | >0.999 | 27 (19.1) | 5 (20.8) | 0.786 | NC | NC | NC |
| csDMARDs, n (%) | 286 (85.4) | 62 (82.7) | 0.593 | 83 (65.9) | 18 (56.3) | 0.312 | 30 (61.2) | 9 (52.9) | 0.578 | 106 (75.2) | 16 (66.7) | 0.451 | 103 (62.0) | 26 (70.3) | 0.450 |
| bDMARDs, n (%) | 124 (37.0) | 43 (57.3) | 0.002 | 37 (29.4) | 19(59.4) | 0.003 | 11 (22.4) | 9 (52.9) | 0.031 | 39 (27.7) | 14 (58.3) | 0.004 | 63 (38.0) | 22 (59.5) | 0.026 |
| . | Peripheral arthritis (n = 410) . | Enthesitis (n = 248) . | Dactylitis (n = 100) . | Root jointadisease (n = 192) . | Axial disease (n = 238) . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | Patients without personal history of psoriasis (n = 335) . | Patients with personal history of psoriasis (n = 75) . | P . | Patients without personal history of psoriasis (n = 194) . | Patients with personal history of psoriasis (n = 54) . | P . | Patients without personal history of psoriasis (n = 70) . | Patients with personal history of psoriasis (n = 30) . | P . | Patients without personal history of psoriasis (n = 162) . | Patients with personal history of psoriasis (n = 30) . | P . | Patients without personal history of psoriasis (n = 19)3 . | Patients with personal history of psoriasis (n = 45) . | P . |
| Any treatment, n (%) | 314 (93.7) | 71 (94.7) | >0.999 | 126 (64.9) | 32 (59.3) | 0.522 | 49 (70.0) | 17 (56.7) | 0.250 | 141 (87.0) | 24 (80.0) | 0.388 | 166 (86.0) | 37 (82.2) | 0.491 |
| NSAIDs, n (%) | 325 (97.0) | 73 (97.3) | >0.999 | 121 (96.0) | 31 (96.9) | >0.999 | 45 (91.8) | 15 (88.2) | 0.643 | 137 (97.2) | 21 (87.5) | 0.064 | 165 (99.4) | 37 (100.0) | >0.999 |
| Systemic GCs, n (%) | 175 (52.2) | 30 (40.0) | 0.073 | 51 (40.5) | 9 (28.1) | 0.226 | NC | NC | NC | NC | NC | NC | NC | NC | NC |
| Local injections of GCs, n (%) | 137 (40.9) | 22 (29.3) | 0.067 | 18 (14.3) | 6 (18.8) | 0.582 | 11 (22.4) | 4 (23.5) | >0.999 | 27 (19.1) | 5 (20.8) | 0.786 | NC | NC | NC |
| csDMARDs, n (%) | 286 (85.4) | 62 (82.7) | 0.593 | 83 (65.9) | 18 (56.3) | 0.312 | 30 (61.2) | 9 (52.9) | 0.578 | 106 (75.2) | 16 (66.7) | 0.451 | 103 (62.0) | 26 (70.3) | 0.450 |
| bDMARDs, n (%) | 124 (37.0) | 43 (57.3) | 0.002 | 37 (29.4) | 19(59.4) | 0.003 | 11 (22.4) | 9 (52.9) | 0.031 | 39 (27.7) | 14 (58.3) | 0.004 | 63 (38.0) | 22 (59.5) | 0.026 |
Shoulder and hip joints. bDMARD: biologic DMARD; csDMARD: conventional synthetic DMARD; GC: glucocorticoid; NC: not collected.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
